PROTOKOLwiki
COMPOUNDS / SARM / S23
SARM

S23

HIGH RISK
BEST FOR:Cutting●●●●●●○○○○6/10
S23 · GTX-007 · S-23 · SARM S23
SARMAndrogenCuttingResearch ChemicalWADA Banned

Potent non-steroidal androgen receptor full agonist developed by GTX; strong anabolic and cutting effects with significant testosterone suppression.

ROUTE / DOSAGE
LOW5mg
STANDARD10-20mg
HIGH30mg
Note: Split into two daily doses due to ~12h half-life; requires PCT after cycle
CYCLE
8-12 weeks followed by PCT do not exceed 12 weeks
BIOAVAILABILITY
~40-50% oral (estimated)
ACTIVE DURATION
12-24h (subjective)
STORAGE
Room temperature dry away from light refrigerate if dissolved in solution
HALF-LIFE
~12 hours (plasma)
DURATION BREAKDOWN
Total8-12 weeks (typical cycle)
Onset1-2 weeks
Come up2-4 weeks
Peak4-8 weeks
Offset1-2 weeks
After effects2-4 weeks (testosterone recovery with PCT)
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
7 documented
Increased muscle hardness and density
Significant fat loss
Enhanced vascularity
Increased strength
Suppressed libido (at higher doses)
Testosterone suppression
Improved bone density
§ 02 — RISKS
Severe testosterone suppression — more pronounced than other SARMs
HDL cholesterol reduction and unfavorable lipid changes
Potential liver enzyme elevation
Hair thinning or accelerated hair loss in predisposed individuals
Acne and skin irritation
Possible infertility or reduced sperm count with prolonged use
§ 03 — INTERACTIONS
Interaction data not yet available for this compound.
§ 04 — SCIENCE

S23 was developed by GTX Pharmaceuticals as part of a SARM program for androgen deficiency and muscle wasting conditions, but never entered clinical trials in humans. Preclinical animal studies demonstrated significant increases in lean body mass, bone mineral density, and fat loss. Evidence in humans is limited to anecdotal reports and underground use; no published clinical trials exist. The compound is notable for causing profound testosterone suppression even at moderate doses, reportedly more severe than other SARMs. Its safety profile, long-term effects, and hepatotoxicity risk remain poorly characterized due to the absence of human pharmacological studies.

§ 06 — SOURCES
[1]
PubMed PMID 9922375
pubmed.ncbi.nlm.nih.gov ↗
[2]
PubMed PMID 16077906
pubmed.ncbi.nlm.nih.gov ↗
[3]
PubMed PMID 32423862
pubmed.ncbi.nlm.nih.gov ↗
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT